Moxifloxacin Retains Antimycobacterial Activity in the Presence of gyrA Mutations | Zendy

Marieta McGrath | Zendy; Nicolaas C. Gey van Pittius | Zendy; Frederick A. Sirgel | Zendy; Paul D. van Helden | Zendy; Robin M. Warren | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Moxifloxacin Retains Antimycobacterial Activity in the Presence of gyrA Mutations

Author(s) -

Marieta McGrath,

Nicolaas C. Gey van Pittius,

Frederick A. Sirgel,

Paul D. van Helden,

Robin M. Warren

Publication year - 2014

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02583-13

Subject(s) - moxifloxacin , antimycobacterial , ofloxacin , mycobacterium tuberculosis , microbiology and biotechnology , dna gyrase , antibacterial agent , tuberculosis , mutant , antibiotics , in silico , in vitro , biology , medicine , chemistry , escherichia coli , genetics , ciprofloxacin , gene , pathology

Moxifloxacin-resistant Mycobacterium tuberculosis mutants were selected in vitro using different concentrations of moxifloxacin. gyrA mutations at codons 88 and 94 were associated with resistance (defined as an MIC of ≥2 μg/ml) (P < 0.0001 and P = 0.0053, respectively). Despite the presence of gyrA mutations, moxifloxacin significantly impedes bacterial growth, supporting its use for the treatment of ofloxacin-resistant M. tuberculosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research